Statins Against Alzheimer’s Diseaseby Amy Wong, MS | January 2, 2013
As the population ages, it is universally acknowledged that some will succumb to the awful fate of Alzheimer’s Disease (AD), a neurological disorder that accounts for 60-80% of all cases of dementia. Characterized by a decline in cognitive and social functions and severe memory loss, AD affects nearly 35% of the population over 85 years of age. Histopathologically, markers of AD include the formation of senile plaques, caused by the extracellular accumulation of amyloid fibrils in the brain, and intraneuronal aggregates of neurofibrillary tangles with lead to progressive brain dysfunction.
Recent figures indicate that as many as 35 million people worldwide have dementia, a value that is projected to almost double within the next two decades. Thus, it is no wonder that medical research is constantly trying to discover the most effective preventative measure to slow progression of the disease. Although the exact cause of AD remains elusive, several risk factors are hypothesized to be involved in its development, including high levels of plasma cholesterol. Indeed, accumulation of cholesterol has been associated with senile plaques and in transgenic models of AD. Taking into account the association between high plasma cholesterol and AD, Tramontine and colleagues recently conducted a study to explore the role of statins — a class of lipid-lowering drugs — in the protection against the disease. Although the positive effects of statins on cardiovascular diseases are well known, their potential neuroprotective effects demand further characterization.
The authors used the experimental intracerebroventricular (ICV) streptozotocin (STZ) animal model to demonstrate metabolic changes that are very similar to those found in the sporadic form of AD. In this model, deficits in learning, memory, and cognitive behavior have been reported. In addition, increased oxidative damage, alterations in glucose utilization and neuronal damage have been described. Molecularly, astrocytes play a fundamental role in glutamate metabolism by regulating extracellular levels of glutamate and intracellular levels of glutamine. They also participate in antioxidant defenses in the production of glutathione, coupled to glutamate metabolism. Changes in neurochemical parameters, such as glutamate uptake, glutamine synthetase activity, and glutathione have been investigated in the disease.
The authors administered 0.1 mL of pravastatin (5 mg/kg) to the animals every two days for four weeks. Serum biochemical measurements, hippocampal tissue samples, glutamine synthetase activity, glutathione levels, and glutamate uptake were examined. It was reported that glutathione content was reduced in the STZ-treated animals about 30% compared with the sham group, indicating the development of oxidative stress. However, administration of pravastatin was able to prevent the effect of STZ on glutathione content. Furthermore, pravastatin was able to prevent the observed decrease in hippocampal glutamine synthetase activity in the STZ treated animals. Finally, STZ-treated rats were found to have reduced total content of glutathione in there hippocampal slices, an effect that was reversed in animal models that were administered with pravastatin.
Glutatmatergic neurotransmission, gluatamate metabolism and antioxidant defense are strongly coupled in the neuroprotection against AD development. The current study suggests that pravastatin can interfere with these parameters by reversing some of the negative effects initiated by the disease. Hopefully with the increasing gains of medical research, future studies will also be able to demonstrate the contribution of statins in reducing cognitive impairment and brain damage in AD patients.
Maccioni RB, Muñoz JP, & Barbeito L (2001). The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Archives of medical research, 32 (5), 367-81 PMID: 11578751
Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, & Mullan MJ (2001). Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. Journal of neuropathology and experimental neurology, 60 (8), 778-85 PMID: 11487052
Tramontina AC, Wartchow KM, Rodrigues L, Biasibetti R, Quincozes-Santos A, Bobermin L, Tramontina F, & Gonçalves CA (2011). The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer’s disease in rats. Journal of neural transmission (Vienna, Austria : 1996), 118 (11), 1641-9 PMID: 21744242
Mental Context – A Delicate Subject
Welcome to the new Brain Blogger! We just completed a complete redesign of our desktop and mobile Brain Blogger sites. Powered by the web-design expertise... READ MORE →
Do not miss out ever again. Subscribe to get our newsletter delivered to your inbox a few times a month.
Like what you read? Give to Brain Blogger sponsored by GNIF with a tax-deductible donation.Make A Donation